KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Equity Average: 2011-2024

Historic Equity Average for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $978.6 million.

  • Supernus Pharmaceuticals' Equity Average rose 7.58% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 7.58%. This contributed to the annual value of $978.6 million for FY2024, which is 8.27% up from last year.
  • According to the latest figures from FY2024, Supernus Pharmaceuticals' Equity Average is $978.6 million, which was up 8.27% from $903.9 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Equity Average ranged from a high of $978.6 million in FY2024 and a low of $670.1 million during FY2020.
  • For the 3-year period, Supernus Pharmaceuticals' Equity Average averaged around $911.2 million, with its median value being $903.9 million (2023).
  • Data for Supernus Pharmaceuticals' Equity Average shows a peak YoY rose of 27.83% (in 2020) over the last 5 years.
  • Over the past 5 years, Supernus Pharmaceuticals' Equity Average (Yearly) stood at $670.1 million in 2020, then grew by 16.45% to $780.4 million in 2021, then climbed by 9.06% to $851.0 million in 2022, then increased by 6.21% to $903.9 million in 2023, then rose by 8.27% to $978.6 million in 2024.